Login to Your Account

NeuroSearch, GlaxoSmithKline Halt Development Of NS2389

By Cormac Sheridan

Wednesday, March 13, 2002
The antidepressant drug development alliance between Danish firm NeuroSearch A/S and partner GlaxoSmithKline plc has hit a bump that will delay progress by several years. The two companies have decided to discontinue development of the neurotransmitter reuptake inhibitor NS2389, which had been in Phase II clinical trials. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription